Cellcor's new approach to immunotherapy links patient and lab; the firm's success is tied to skirting the FDA bottleneck
|It's been eight years since Michael Osband, then a professor at Boston University, started down the road to biocare. He was experimenting with in vitro immunization of human lymphocytes: taking out white blood cells, sensitizing them to a particular antigen, then putting them back into the body, where their enhanced properties could be put to use. He discovered that lymphocytes, once removed from the body, could be treated in ways that would be harmful in the body, but not to cells in a petri...|
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?